Atorvastatin in Patients With Ulcerative Colitis

Tanta University

Status and phase: Completed; Phase 2

Conditions: Inflammatory Bowel Diseases

Treatments: Drug: Atorvastatin 80mg

Study type: Interventional

Funder types: Other

Identifiers

NCT05561062

9/22021

Details and patient eligibility

About

Ulcerative colitis (UC) is an idiopathic, chronic inflammatory disease characterized by diffused inflammation of the colon and rectum mucosa; however, the exact underlying mechanisms of UC remain poorly understood. Statins exert numerous pleiotropic effects including anti-inflammatory, antioxidant properties, endothelial function improvement, and immunomodulation independent of their basic lipid-lowering property.

Enrollment: 50 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≥ 18 years
• Both male and female will be included
• Negative pregnancy test and effective contraception

Exclusion criteria

• Breastfeeding
• Significant liver and kidney function abnormalities
• Colorectal cancer patients
• Patients with severe UC
• Patients taking rectal or systemic steroids
• Patients taking immunosuppressives or biological therapies

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

50 participants in 2 patient groups

Control Group

No Intervention group

Description:

This group will take 1 g mesalamine three times daily

Atorvastatin group

Active Comparator group

Description:

This group will take 1 g mesalamine three times daily and atorvastatin 80 mg once daily

Treatment:

Drug: Atorvastatin 80mg